EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes

Henrik Maagensen iD, Johanne S Jensen, Stine O Høyerup, Anne C B Thuesen, Jesper Krogh, Jens J Holst, Henrik Vestergaard, Peter Rossing, Torben Hansen, Filip K Knop, Sofie Hædersdal, Tina Vilsbøll iD

Diabetes Care · 01.09.2025 · 48 (9) · 1536-1544

DOI: 10.2337/dc25-0737 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 03.07.2025. Verfasst von Henrik Maagensen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glycosuria. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Pathogenic variants of HNF1A cause maturity-onset diabetes of the young type 3 (HNF1A-MODY; also known as MODY3). Individuals with HNF1A-MODY are primarily treated with sulfonylureas; however, little is known about the effect of sodium–glucose cotransporter 2 (SGLT2) inhibitors in HNF1A-MODY. Interestingly, HNF1A-MODY is associated with increased glucosuria, which has been attributed to lower expression of SGLT2 as observed in HNF1A-knockout mice. We investigated the impact of acute SGLT2 inhibition on glucosuria in individuals with HNF1A-MODY or type 2 diabetes. RESEARCH DESIGN AND METHODS In a randomized, double-blind, crossover study, individuals with HNF1A-MODY or type 2 diabetes underwent two three-step hyperglycemic clamps targeted at 1-h periods of 10, 14, and 18 mmol/L glucose with and without acute SGLT2 inhibition (25 mg empagliflozin or placebo administrated 2 h before clamp procedures). RESULTS Eleven individuals with HNF1A-MODY (age [mean ± SD] 49 ± 15 years; glomerular filtration rate [GFR; mean ± SD] 113 ± 18 mL/min) and 10 individuals with type 2 diabetes (age 63 ± 7 years; GFR 103 ± 27 mL/min) were included. During the 3-h hyperglycemic clamp, SGLT2 inhibition increased urinary glucose excretion in both groups (HNF1A-MODY: 24.5 g [95% CI 20.6, 28.3]; type 2 diabetes: 23.5 g [95% CI 20.4, 26.5]). The effect of SGLT2 inhibition was not significantly different between the groups (1.0 g [95% CI −3.5, 5.6]; P = 0.6). CONCLUSIONS The robust effect of SGLT2 inhibition on urinary glucose excretion in participants with HNF1A-MODY points to SGLT2 inhibition as a relevant glucose-lowering treatment strategy in individuals with HNF1A-MODY.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlycosuriaHumansDouble-Blind MethodMaleMiddle AgedHepatocyte Nuclear Factor 1-alphaFemaleGlucose Clamp TechniqueGlucosidesCross-Over StudiesAdultBenzhydryl CompoundsSodium-Glucose Transporter 2

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHepatocyte Nuclear Factor 1-alphaGlucosidesBenzhydryl CompoundsempagliflozinSodium-Glucose Transporter 2HNF1A protein, humanSLC5A2 protein, human

Autor:innen und Institutionen

  • Copenhagen University Hospital-Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Clinic for Pituitary Disorders, Department of Medicine, Zealand University Hospital, Køge, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark.

ORCID-Profile: Henrik Maagensen, Tina Vilsbøll

Zitieren

APA

Maagensen, H., Jensen, J. S., Høyerup, S. O., Thuesen, A. C. B., Krogh, J., Holst, J. J., Vestergaard, H., Rossing, P., Hansen, T., Knop, F. K., Hædersdal, S., & Vilsbøll, T. (2025). Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes. Diabetes Care, 48(9), 1536-1544. https://doi.org/10.2337/dc25-0737

Vancouver

Maagensen H, Jensen JS, Høyerup SO, Thuesen ACB, Krogh J, Holst JJ, et al. Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes. Diabetes Care. 2025;48(9):1536-1544. doi:10.2337/dc25-0737

BibTeX
@article{Maagensen2025,
  author = {Maagensen, Henrik and Jensen, Johanne S and Høyerup, Stine O and Thuesen, Anne C B and Krogh, Jesper and Holst, Jens J and Vestergaard, Henrik and Rossing, Peter and Hansen, Torben and Knop, Filip K and Hædersdal, Sofie and Vilsbøll, Tina},
  title = {Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes},
  journal = {Diabetes Care},
  year = {2025},
  volume = {48},
  number = {9},
  pages = {1536--1544},
  doi = {10.2337/dc25-0737}
}
Kostenlos starten →